Allogene to Present Positive Phase 1 Data for Investigational CAR T-cell Therapy ALLO-715
ALLO-715, an investigational donor-derived CAR T-cell therapy by Allogene Therapeutics, has a manageable safety profile and promising preliminary efficacy results in people with relapsed or refractory multiple myeloma, a Phase 1 clinical trial has shown. The results will be presented at the 62nd Annual Meeting…